IMIC(000516)2023-04-18 16:00Financial Performance - Total assets increased by 1.48% to RMB 13,460,535,622.49 compared to the adjusted figure of RMB 13,264,224,493.51[6] - Equity attributable to shareholders of the listed company decreased by 1.55% to RMB 4,184,794,966.92 from the adjusted figure of RMB 4,250,695,185.16[6] - Net profit for the period was RMB -95,739,550.26, compared to RMB -432,820,830.09 in the same period last year[10] - Diluted earnings per share were RMB -0.0291, compared to RMB -0.1882 in the same period last year[10] - The company achieved a revenue of 1,059.09 million yuan in Q1 2023, a year-on-year increase of 247.40%[22] - Net profit attributable to the parent company in Q1 2023 was -74.74 million yuan, a year-on-year increase of 82.55%[22] - Total operating revenue for the current period is RMB 1,059,092,457.42, a significant increase from RMB 304,865,465.75 in the previous period[30] - Net profit attributable to the parent company's owners is RMB -74,740,547.17, compared to RMB -428,421,595.49 in the previous period[45] - Basic earnings per share for the current period is RMB -0.0328, an improvement from RMB -0.1882 in the previous period[45] - Revenue for the reporting period was 1,059,092,457.42 yuan, a 247.40% increase year-over-year[52] - Net profit attributable to shareholders improved to -74,740,547.17 yuan, an 82.55% improvement compared to the same period last year[52] - Basic earnings per share improved to -0.0328 yuan, an 82.57% increase compared to the same period last year[52] - Weighted average return on equity improved to -1.75%, a 6.59 percentage point increase from the same period last year[52] Operating Costs and Expenses - Operating costs increased by 78.92% year-on-year due to the new medical campuses and business expansion of the medical subsidiaries[9] - Taxes and surcharges increased by 151.05% year-on-year, mainly due to increased property tax provisions by the subsidiary Xi'an International Medical Center Co., Ltd.[9] - Operating costs for the current period are RMB 972,385,400.75, up from RMB 543,474,761.78 in the previous period[30] - R&D expenses for the current period are RMB 3,325,497.80, up from RMB 2,358,282.37 in the previous period[30] - Taxes and fees paid increased to 17,689,687.01 yuan, up from 12,038,564.57 yuan in the same period last year[47] - Employee compensation and benefits paid were 398,160,903.03 yuan, slightly higher than the previous year's 392,733,192.48 yuan[47] Cash Flow - Net cash flow from operating activities increased by 208.07% year-on-year due to significant revenue growth from medical subsidiaries[9] - Net cash flow from financing activities increased by 565.41% year-on-year due to increased cash received from loans by the company and its subsidiaries[9] - Cash received from selling goods and providing services is RMB 804,974,363.77, up from RMB 350,233,145.31 in the previous period[45] - Operating cash flow increased significantly to 222,931,373.21 yuan, a 208.07% increase compared to the same period last year[52] - Net cash flow from financing activities was 130,029,914.30 yuan, compared to -27,939,026.41 yuan in the same period last year[48] - Cash and cash equivalents decreased by 2,154,077.89 yuan, ending the period at 1,181,624,032.36 yuan[48] - Investment cash outflow was 379,185,244.06 yuan, primarily for fixed assets and long-term investments[47] Asset and Liability Changes - Accounts receivable increased by 39.85% compared to the end of the previous year, mainly due to increased medical insurance settlement receivables[22] - Prepayments increased by 151.28% compared to the end of the previous year, mainly due to increased prepaid operating expenses[22] - Other current assets increased by 30.35% compared to the end of the previous year, mainly due to increased deductible input tax[22] - Fixed assets increased by 40.49% compared to the end of the previous year, while construction in progress decreased by 96.34%, mainly due to the transfer of completed projects to fixed assets[22] - Other non-current assets increased by 32.50% compared to the end of the previous year, mainly due to increased prepayments for equipment[22] - Minority interests decreased by 17,655.36% compared to the end of the previous year, mainly due to reduced minority interest losses[22] - Total current liabilities amounted to 5,744.59 million yuan, while total non-current liabilities amounted to 3,552.03 million yuan[15] - Total liabilities and owner's equity amounted to 13,460.54 million yuan[15] - Total assets at the end of the period are RMB 13,460,535,622.49, slightly higher than RMB 13,264,224,493.51 at the beginning of the period[41] - Fixed assets at the end of the period are RMB 7,986,846,562.55, a significant increase from RMB 5,684,908,536.84 at the beginning of the period[41] - Total current assets at the end of the period are RMB 3,915,116,034.38, compared to RMB 3,711,899,394.23 at the beginning of the period[41] - Total non-current assets at the end of the period are RMB 9,545,419,588.11, slightly lower than RMB 9,552,325,099.28 at the beginning of the period[41] Investment and Fair Value Changes - Investment income decreased by 98.30% year-on-year due to reduced financial product income[9] - Fair value change income increased by 210.03% year-on-year due to increased fair value change income from held trading financial assets[9]